LintonPharm Starts China Trial of Candidate for Bladder Cancer
April 13, 2021 at 06:10 AM EDT
LintonPharm, a Guangzhou biopharma, was approved to start a China Phase I/II clinical trial of catumaxomab to treat recurrent Non-Muscle-Invasive Bladder Cancer (NMIBC). The trial will enroll patients whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure. In 2020, LintonPharm started a China Phase III trial of catumaxomab. an immunotherapy, in patients with advanced gastric cancer. LintonPharm develops innovative T cell engaging bispecific antibodies, aiming to turn malignant cancers into manageable or curable diseases. More details.... Share this with colleagues: // //
